Adempa 25 mg (Tablet)
Unit Price: ৳ 50.00 (1 x 10: ৳ 500.00)
Strip Price: ৳ 500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin |
| Company | Unimed unihealth pharmaceuticals ltd |
| Also available as |
Product Title
- Adempa 25 mg Tablet
Categories
- Medicine
- Pharmaceutical
Description
- Adempa is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- It is also used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Dosage and Administration
- Recommended dose is 10 mg once daily, taken in the morning, with or without food.
- In patients tolerating Adempa, the dose may be increased to 25 mg once daily.
- In patients with volume depletion, correcting this condition prior to initiation of Adempa is recommended.
Mode of Action
- Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor.
- It reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion.
- Contributes to reduced hyperglycemia, weight loss, and reduced blood pressure.
Contraindications
- Contradicted in patients with history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients.
- Severe renal impairment, end-stage renal disease, or dialysis.
Side Effects
- Common adverse reactions include urinary tract infections and female genital mycotic infections.
- Other common side effects are dehydration, hypotension, weakness, dizziness, and increased thirstiness.
Interaction
- Co-administration with diuretics resulted in increased urine volume.
- With insulin or insulin secretagogues increases the risk for hypoglycemia.
- Monitoring glycemic control with urine glucose tests is not recommended.
- Interference with 1,5-anhydroglucitol (1,5-AG) assay is not recommended.
Pregnancy and Lactation
- No adequate and well-controlled studies in pregnant women.
- Should be used during pregnancy only if potential benefit justifies potential risk to the fetus.
- Not recommended when breastfeeding.
Precautions and Warnings
- Assessment of renal function is recommended prior to initiation and periodically thereafter.
- Should not be initiated in patients with an eGFR less than 45 ml/min/1.73 m^2.
- No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m^2.
Overdose Effects
- Supportive measures should be employed in the event of an overdose.
- Removal of Adempa by hemodialysis has not been studied.
Therapeutic Class
- Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
- Keep in a cool & dry place (below 30°C).
- Protected from light & moisture.
- Keep out of the reach of children.
Chemical Structure
- Molecular Formula: C23H27ClO7
Common Questions
- What is Adempa 25 mg Tablet?
- Adempa 25 mg Tablet is used for?
- Are there any pregnancy warnings?
- Are there any breast-feeding warnings?
- Does this affect kidney function?
- Does this affect liver function?
- Quick Tips